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Edited by Horst FeldmannAbstract The eﬀect on the stability of alternative transcripts of
diﬀerent mutations of the NDUFS4 gene in patients with Leigh
syndrome with complex I deﬁciency is presented. Normally, two
NDUFS4 splice variants are degraded by nonsense mediated
mRNA decay (NMD) while a third form does not trigger
NMD degradation. In a patient with a premature termination
codon in exon 1, all the three splice variants are up-regulated.
The present is the ﬁrst case of a nonsense mutation leading to
the abrogation of NMD, which can represent an additional event
to be considered in the evaluation of clinically relevant muta-
tions.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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An increasing amount of evidences indicate that nucleotide
changes in the coding sequence can aﬀect the pathway of
mRNA splicing or mRNA stability [1]. A survey performed
more than a decade ago found that approximately 15% of all
point mutations responsible for human genetic diseases cause
alternative RNA splicing [2], which is likely to be an underes-
timate because it is now known that aberrant splicing is also
caused by mutations that modify exonic splicing regulatory
elements (ESE) [1]. Faulty splicing, as well as nonsense or
frameshift mutations can generate premature termination co-
dons (PTCs) which usually trigger nonsense mediated mRNA
decay (NMD) [3] or nonsense associated altered splicing
(NAS) [4]. NMD is a highly conserved surveillance process
leading to detection and selective reduction in the abundance
of PTC-harbouring mRNAs to prevent the synthesis of abnor-
mal proteins [5]. However, NMD has also been involved in
degrading natural substrates, meaning that it can represent
an additional mode of regulating gene expression [6,7].Abbreviations: NDUFS4, NADH-ubiquinone oxidoreductase Fe–S
protein 4; PTC, premature termination codon; NMD, nonsense med-
iated decay; EJ, exon junction; ESE, exonic splicing enhancer; ESTs,
expression sequence tags
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doi:10.1016/j.febslet.2005.05.035The NDUFS4 gene encodes for one of the 46 structural sub-
units of the mitochondrial NADH: ubiquinone oxidoreductase
(complex I, E.C.1.6.5.3) [8,9]. This gene is a hotspot of muta-
tions in an autosomal recessive form of a multisystemic fatal
infantile disorder, the Leigh syndrome [10–13].
Here, we present a study on the eﬀects of three diﬀerent
mutations on the splicing and stability of the NDUFS4 tran-
scripts. In particular, a nonsense mutation introducing a
PTC, rather than eliciting nonsense mediated mRNA decay,
stabilises and unmasks the existence of alternative NDUFS4
transcripts.2. Materials and methods
2.1. Cell culture and RT-PCR analysis
Fibroblasts from skin biopsies of three patients harbouring three dif-
ferent homozygous mutations, respectively, a nonsense mutation
44G > A (W15X) in the ﬁrst exon [12], a 466–470DuplAAGTC in the
exon 5 [10] and a 289delG introducing a stop codon in the exon 3
[11] of the NDUFS4 gene and from a healthy individual as a control
were grown as described [14]. Total RNA, extracted by the High Pure
RNA isolation Kit (Roche) was reverse transcribed by the oligo-dT
primer with AMV-Reverse Transcriptase-RNAseH minus (New Eng-
land Biolabs). PCR ampliﬁcation of the NDUFS4 canonical entire
open reading frame (ORF) was performed using 18k-F and 18k-R
primers (Table 1). All the PCR ampliﬁcations were performed with
Taq DNA Polymerase (Eppendorf) with primers and Tm as listed in
Table 1. To speciﬁcally amplify the SV1 and SV2 isoforms, F-30
primer designed within exon 1 with R-crypto primer within the cryp-
to-exon, were used after a ﬁrst round of PCR with 18k-F and 18k-R
primers (Table 1). The ampliﬁcation products were gel extracted by
QIAquick gel Extraction Kit (Qiagen), cloned by TAcloning Kit
(InVitrogen) and sequenced on an automated ABI 310 sequencer
(Applied Biosystems).
The quantitation of the NDUFS4 isoforms, SV1, SV2, SV3 and of
the canonical transcript normalized to GAPDH mRNA was per-
formed by real-time-PCR with the iQ SYBRgreen Supermix (BioRad)
on a BIORAD iCycler iQ instrument. The primers sequences and
annealing temperature used are listed in Table 1. The PCR conditions
were: 2000 at 94 C, 3000 at 59 C, 4500 at 72 C for 45 cycles.
2.2. In vitro splicing of NDUFS4 minigene
Constructs including either the single NDUFS4 exon1 or exons 1, 2,
crypto and 3, were cloned in the pSPL3 vector [15]. Exons and ﬂanking
sequences were ampliﬁed from genomic DNA using restriction site-
tagged primers. The 44G > A mutation was introduced in both con-
structs by cloning exon 1-containing region ampliﬁed from genome
of patient with 44G > A mutation. The constructs were transiently
transfected in Cos-7 cells using Metafectene (Biontex). After 48 h, total
RNA was isolated with TRIzol (Invitrogen) and reverse transcribed
primed by oligo-dT. The PCR ampliﬁcation of pSPL3-containing
exon1 was performed with EXPANDe LongTemplate (Roche) usingblished by Elsevier B.V. All rights reserved.
Table 1
Primer sets and annealing temperatures for PCR ampliﬁcations
Primer set and name 5 0 ﬁ 3 0 Sequence Fragment size (bp) Annealing temperature (C)
Complete ORF
18k-F 5 0-ATGGCGGCGGTCTCAATGTC-30 528 53
18k-R 5 0-TATTTTGTGGATACTCTTGTTC-30
SV1 and SV2
F-30 5 0-GTGGTACTGAGGCAGACGTTGT-30 310 (SV1) 59
R-crypto 5 0-ATGGTGACCGGATGAAGTCCTC-30 227 (SV2)
Minigene Ex1
F-SD6 5 0-TCTGAGTCACCTGGACAACC-30 355 (SDV-Ex1-SAV) 59
R-SA2 5 0-ATCTCAGTGGTATTTGTGAGC-30 257 (SDV-SAV)
Minigene Ex1-2-cry-3
18k-F 5 0-ATGGCGGCGGTCTCAATGTC-30 442 (Ex1-2-cry-3) 58
R-282 5 0-TCCAGAACTGCATGTTATTGCG-30 270 (Ex1-2-3)
Untranscribed pSPL3




F-Ex2-Ex3-Real 5 0-TGATGAAAAATTGGATATCACTAC-30 111 59
M18k2B 5 0-TTTACTCCAGACTGCATGTTATTGC-3 0
SV1
F840-Real 5 0-CCAAGCCTGGAACTTGCTAC-30 225 59
M18k2B 5 0-TTTACTCCAGACTGCATGTTATTGC-3 0
SV2
F757nt-Real 5 0-TGATGAAAAATTGGCATTTGGAG-30 200 59
M18k2B 5 0-TTTACTCCAGACTGCATGTTATTGC-3 0
SV3
F-Ex1-Ex3-Real 5 0-GTTCCGACCAGGATATCACTAC-30 109 59
M18k2B 5 0-TTTACTCCAGACTGCATGTTATTGC-3 0
Minigene Ex1
F-30 5 0-GTGGTACTGAGGCAGACGTTGT-30 242 59
R-SA2 5 0-ATCTCAGTGGTATTTGTGAGC-30
GAPDH
GLIC-1F 5 0-GAAGGTGAAGGTCGGAGT-3 0 110 59
GLIC-4R 5 0-CATGGGTGGAATCATATTGGAA-30
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ﬁcation of the spliced product was performed with F-30 and R-SA2
and normalised to GAPDH mRNA. For the minigenes containing
exons 1, 2, crypto and 3, the RT-PCR reactions were carried out for
18 cycles with F-30 and R-282 and the spliced products were norma-
lised to GAPDH mRNA (Table 1). Transfection eﬃciency was evalu-
ated by normalising the spliced products to an untranscribed region
generated by pSPL3-F- and pSPL3-R (Table 1).Table 2










In parenthesis the distances in nucleotides (nt) between the PTC and the closes
predicted to escape NMD. +/, NMD commitment not easily predictable.2.3. Inhibition of protein synthesis
Primary ﬁbroblasts from the two patients and a control individual
were grown to 80% conﬂuence. To assess the sensitivity to
NMD, puromycin (100 lg/ml) was added to the colture medium.
Puromycin was then removed after 12 h by medium replacement,
the cells were let to recover in puromycin-free medium and total
RNA was extracted at diﬀerent times (4, 8 and 12 h) after puromy-
cin removal.–55nt rule’’
44G > A 466-470Dupl
(54nt EJ2) (126nt EJ4)
/+ +
(54nt EJ2) (44nt EJ3)
/+ –
(54nt EJ2) (STOP last exon)
/+ –
(54nt EJ2) (157nt EJ3)
/+ +
t exonic junction (EJ) is reported. +, predicted to undergo to NMD; ,
Fig. 1. Identiﬁcation of NDUFS4 splice variant SV1, SV2 and SV3. (A) RT-PCR of the entire NDUFS4 ORF from control (Ctrl) and the 44G > A
patient. (B) Representation of alternative transcripts generated by the NDUFS4 gene indicated as connecting lines. (C) RT-PCR speciﬁc for crypto-
containing transcripts in ﬁbroblasts of a healthy child (Ctrl) and of the patients harbouring, respectively, the 44G > A, 466–470Dupl and 289DelG
mutations. Localization and names of used PCR primers are indicated in (B).
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performed on ﬁbroblasts cultures from the two patients and from a
normal individual after 12 h incubation with puromycin (100 lg/ml).3. Results
3.1. Identiﬁcation of NDUFS4 splice variants
In the patient harboring the 44G > A mutation, RT-PCR
ampliﬁcation of the entire NDUFS4 ORF (528nt) showed, in
addition to the expected one, three products (Fig. 1A).
Sequencing analysis of these products revealed that they were
alternative transcripts originating from the NDUFS4 gene.
The ﬁrst product of 700 bp presented an insertion of 172 bp
at position +186 of the coding sequence that we named cryp-
to-exon. This corresponds to a splice variant SV1 of 840nt
(Fig. 1B). PCR-sequencing analysis of the corresponding
genomic region revealed that the crypto-exon was localized
at 1193nt of intron 2 (Fig. 1B). The Splice Site Prediction anal-
ysis tool (http://www.fruitﬂy.org/seq_tools/splice.html) pre-
dicted a score of 0.99 for the exon 2 donor site and a score
of 1.00 for exon 3 acceptor site. The prediction for the accep-
tor and the donor sites of the crypto-exon gave a score of 0.96and 0.90, respectively, implying that, in vivo, the eﬃciency of
the junction formation between exon 2 and crypto can com-
pete eﬃciently with the canonical junction between exons 2
and 3. The second isoform, SV2, (Fig. 1B) corresponds to a
758nt transcript containing a shortened crypto-exon, lacking
the ﬁrst 83nt, that we named mini-crypto. It represents the
product of an alternative 3 0 splice site. In all RT-PCR reac-
tions performed with speciﬁc primers for exons 1 and 5, both
in normal and patients samples, a third form, named SV3, was
always present. Sequencing analysis revealed that it corre-
sponds to a transcript lacking the entire exon 2 (Fig. 1). To
check for the presence of SV1 and SV2 in normal subjects as
well as in the patient harboring the 466–470DuplAAGTC and
289delG, nested RT-PCR reactions were performed. Sequenc-
ing analysis revealed that the 310 bp and 227 bp fragments
corresponded, respectively, to SV1 and SV2, and conﬁrmed
that they were present in all the samples analyzed (Fig. 1C).
A search in the human and non-human EST database
(ESTdb) showed that the SV1 and SV3 are present only in hu-
mans – clone BM471270 and BU677366.1, respectively,
according to recent data supporting the low evolutionary con-
servation of alternative splicing patterns [16] while SV2 was
not represented in human ESTdb.
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The algorithm ESEﬁnder 2.0identiﬁed a newly introduced
consensus motif AGCGGA – mutation 44G > A is underlined
– (score 3.069, Threshold 2.67) for the splicing factor SRp55
[17].We set up an in vitro splicing assaybasedon thepSPL3plas-
mid [15] introducing mutated or wild-type exon 1 with adjacent
intronic sequences. The results obtained did not reveal any dif-
ference in size or in quantity of the spliced product (Fig. 2A),
as also conﬁrmed by Real-time assay (not shown). We also gen-
erated a ‘‘minigene’’ containing exons 1, 2, crypto and exon 3 to
more faithfully resemble the in vivoNDUFS4 gene organization
that was used to transfect Cos 7 cells. RT-PCR analysis in con-
ditions chosen to avoid saturation of the reactionwas performed
by amplifying the mutant and wild-type spliced products and
normalizing toGAPDHmRNA (Fig. 2B). The results obtained,
again did not show any qualitative or quantitative (not shown)
diﬀerence comparing the expression between the wild-type and
mutated exon 1-containing constructs (Fig. 2B).
3.3. Inhibition of protein synthesis
Fibroblasts from the 3NDUFS4mutated patients and a con-
trol individual were incubated with puromycin which has been
shown to inhibit NMD [18]. A 12 h incubation of normal and
patients ﬁbroblasts with puromycin (100 lg/ml) fully restored
the SV1 and SV2 in normal and in both the 466–470Dupl and
289DelG patients, whereas the transcripts remained unchanged
in the patient harbouring the 44G > A (Fig. 3A). Since SV3 was
present at very low levels changes of its expression have been
evaluated only by real time PCR (see below). RT-PCR analysis
after removal of puromycin at diﬀerent times showed a progres-
sive restoration of the sensitivity of SV1 and SV2 transcripts to
NMD only in the normal ﬁbroblasts but not in the ﬁbroblasts
harboring the 44G > A mutation (Fig. 3B).Fig. 2. RT-PCR of Cos-7 cells transfected with the wild-type (Wt) and mutan
reaction using a beta-globin exon cloned in pSPL3. (B) Minigene containi
canonical NDUFS4 transcript, the only isoform present in Cos7 cells.3.4. Real-time PCR of NDUFS4 transcripts
Real-time PCR analysis was carried out to quantify the
expression level of NDUFS4 transcripts in normal and patients
ﬁbroblasts. It was not possible to perform the analysis in the
ﬁbroblasts harbouring the 289DelG since they lost viability.
Fig. 4A reports the ratios of SV1, SV2, SV3 and canonical
mRNA normalized with respect to the GAPDH mRNA in the
patients relative to the control individual as obtained by real-
time-PCR. The results indicated that in the case of 44G > A
mutation, there was an up-regulation of 8 fold for SV1 and
SV2 and 6 fold for SV3 isoform whilst the canonical form re-
mained unaltered. In the case of the 466–470Dupl mutation,
all the NDUFS4 isoforms were expressed approximately at the
same level as in the normal control sample. When the protein
synthesis inhibitor puromycin was added to the colture medium
(Fig. 4B), an up-regulation of SV1 and SV2 of 7 and 5 fold,
respectively, was evident in the control sample. This up-regula-
tion was present, although to a lesser extent probably owing to
the poor growth of these cells, also in 466–470Dupl ﬁbroblasts
but not in 44G > A harboring ﬁbroblasts where all the tran-
scripts were unaﬀected by the inhibition of protein synthesis.
The level of SV3was on theother handunaﬀected bypuromycin.4. Discussion
In the present work, we show the eﬀects of diﬀerent muta-
tions on the expression and the stability of alternative mRNA
isoforms of the NDUFS4 gene (Fig. 5B). Mutations in the
NDUFS4 gene have been described to prevent the synthesis
of the protein [14]. This was ascribed to inability to produce
a full-length protein in the patient harbouring the 44G > A
substitution, NMD of the canonical transcript caused by at (Mut)NDUFS4 exon 1. (A) Minigene containing only exon 1. Control
ng Exons 1, 2, crypto and 3. No reagent lane shows the endogenous
Fig. 3. RT-PCR analysis of the eﬀect of puromycin on the stability of the NDUFS4 transcripts. (A) Control and patients harbouring, respectively,
the 44G > A, 466–470Dupl and 289DelG mutations either untreated (1–4) or treated (5–8). (B) Fibroblasts from Control (1–5) and 44G > A patient
(6–10). After 12 h of puromycin incubation (lanes 2, 7) puromycin was removed from the medium and the RNA samples were analysed after 4 h
(3, 8), 8 h (4, 8), 12 h (5, 10), (1, 6, untreated).
Fig. 4. Real-time PCR assays for NDUFS4 transcripts in control and
patients ﬁbroblasts. (A) Results are reported as the relative expression
of the four NDUFS4 transcripts with respect to GAPDH mRNA in all
the patients, with the level in control referred to as 1, and shown as
means ± s.d. (B) Results are reported as relative expression of the four
NDUFS4 and GAPDH transcripts in all the puromycin treated
samples with respect to the untreated ones and referred to a standard
curve derived from a dilution series of GAPDH cDNA containing
plasmid, and shown as means ± s.d. All the experiments were run in
triplicate and the values are the mean results from six independent
experiments. The data were analysed using Students t test, and
*P < 0.01 and **P < 0.05 were considered to indicate signiﬁcant
diﬀerences.
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tion caused by 466–470DuplAAGTC [14]. In the present study,
we have detected two novel splice variants, SV1 and SV2,
resulting from the insertion of a crypto-exon which uses two
alternative acceptor sites, at an abnormally high level in the
presence of the 44G > A substitution. Nested RT-PCR assays
showed that SV1 and SV2 are present even in Dupl466–470
and 289delG patients and in the normal control subject. A
third splice variant, SV3, detected in all the subjects analysed,
derived from the skipping of exon 2. Quantitation of the diﬀer-
ent splice variants by real-time PCR showed that the relative
expression of SV1, SV2 and SV3 was highly increased – from
6 (SV3) to 8 fold (SV1 and SV2) – with respect to control
housekeeping gene when the 44G > A mutation is present,
whilst the canonical transcript was normally represented. As
the 44G > A mutation introduces a putative ESE we set up
an in vitro splicing system to evaluate the eﬀect of this regula-
tory splicing element on NDUFS4 gene splicing pathway. This
system showed, however, that the newly introduced regulatory
element did not per se activate aberrant splicing and suggested
instead the existence of a nonsense codon-speciﬁc up-regula-
tory mechanism acting independently of ESE introduction.
Experiments with the translation inhibitor puromycin, com-
monly used to stabilise transcripts undergoing degradation
by NMD, showed that SV1 and SV2 are conveyed to NMD
whereas SV3 is insensitive to puromycin. Several papers sug-
gest that when PTCs are followed by an intron that is located
more than 50–55nt downstream, this mRNA is degraded by
NMD [3,19]. In wild-type gene, SV1, SV2 and SV3 mRNAs
carry stop codons located in exon 3, mini-crypto and exon 3,
respectively (Fig. 5B). According to the 50–55nt rule (see Ta-
ble 2), in both normal and Dupl466–470 samples, SV1 and SV3
both are bona ﬁde candidates of NMD having stop codons
126nt and 157nt upstream exonic-junction (EJ) 4, respectively.
SV2 should be normally stable having a stop codon 44nt up-
stream from EJ3 (Fig. 5B). In the patient harbouring the
44G > A mutation, all the NDUFS4 isoforms should be insen-
sitive to NMD degradation having a PTC 54nt upstream the
ﬁrst EJ. However, the NMD commitment in the presence of
the 44G > A mutation is not easily predictable since the PTC
falls just in the 50–55nt boundary where no safe prediction
on NMD sensitivity can be made. Our data show in fact, that
in the patient with 44G > A mutation, SV1, SV2 and SV3 were
all up-regulated. In experiments with puromycin (Fig. 4B) in
Fig. 5. (A) Organisation of NDUFS4 gene. (B) Schematic representation of the PTCs positions in SV1, SV2, SV3 and their relative distances to the
next exonic junctions, EJs.
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but, on the contrary, SV2 was upregulated and SV3 was insen-
sitive. These data indicate that the determinants of NMD are
more complex than it would be predicted simply on the basis
of ‘‘50–55nt boundary rule’’. This has been reported to happen
for several other genes such as TPI [20], b-globin [21], BRCA1
[22], TCR-b [23], ﬁbrinogen Aa-chain and ALG3 transcripts
[24]. Our results add evidences of additional transcripts that
do not obey to the ‘‘50–55nt boundary rule’’.
Our ﬁndings suggest that SV3 degradation is independent
from the cytoplasmic translation and the existence of addi-
tional unidentiﬁed determinants that function to modulate
the NMD sensitivity for SV2. The fate of the SV2 in
Dupl466–470 and in normal samples is probably the result
of a more complex regulation. In SV2 there is an additional
not-overlapping ORF of 117aa starting from an AUG lo-
cated at the last three nucleotides of mini-crypto. This
ORF, which is not far from the canonical stop codon could
confer altered response to NMD commitment. Translation
reinitiation was previously found to stabilize PTC-mutated
transcripts [20,25]. When the 44G > A mutation is present,
for all the NDUFS4 isoforms, it determines an apparent re-
turn to the 50–55nt rule in the NMD commitment. In addi-
tion, the same mutation creates a PTC in close proximity to
the canonical AUG which can represent a further determi-
nant in NMD resistance [26]. This is consistent with theﬁndings that puromycin failed to enhance the SV1 and
SV2 levels in the case of 44G > A ﬁbroblasts whilst it in-
duced an up-regulation of these transcripts both in
Dupl466–470 and in 289DelG patients (Fig. 4B) (see also
[14]). In conclusion, in evaluating pathogenicity or the clini-
cal relevance of speciﬁc mutations the possibility of interfer-
ence with normal commitment to NMD of splice variants
can be considered as an additional mechanism of mutations
in hereditary diseases.
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